JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

Home・Akciju saraksts・Denali Therapeutics Inc

Denali Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

20.8 -7.6

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.62

Max

22.27

Galvenie mērījumi
By Trading Economics
Ienākumi	-2.8M -127M
Darbinieki	517
EBITDA	-12M -134M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+45.12% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 25. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	973M 3.2B
Iepriekšējā atvēršanas cena	28.4
Iepriekšējā slēgšanas cena	20.8

Ziņu noskaņojums

By Acuity

63%

37%

305 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

13.355 / 16.44 Atbalsts un pretestība

Denali Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. febr. 23:11 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026. g. 3. febr. 23:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. febr. 23:50 UTC

Tirgus saruna

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026. g. 3. febr. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026. g. 3. febr. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026. g. 3. febr. 23:38 UTC

Peļņas

AMD Sales Climb on Help From Data-Center Business -- Update

2026. g. 3. febr. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026. g. 3. febr. 23:27 UTC

Iegādes, apvienošanās, pārņemšana

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026. g. 3. febr. 23:25 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026. g. 3. febr. 23:23 UTC

Iegādes, apvienošanās, pārņemšana

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026. g. 3. febr. 23:22 UTC

Iegādes, apvienošanās, pārņemšana

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026. g. 3. febr. 23:19 UTC

Tirgus saruna

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026. g. 3. febr. 23:19 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. febr. 22:56 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026. g. 3. febr. 22:40 UTC

Peļņas

Amdocs Extends Collaboration With T-Mobile

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q Adj EPS $1.81

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q Rev $1.16B

2026. g. 3. febr. 22:39 UTC

Peļņas

Amdocs 1Q EPS $1.45 >

2026. g. 3. febr. 22:38 UTC

Peļņas

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026. g. 3. febr. 22:30 UTC

Iegādes, apvienošanās, pārņemšana

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026. g. 3. febr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026. g. 3. febr. 22:14 UTC

Peļņas

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026. g. 3. febr. 22:13 UTC

Peļņas

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026. g. 3. febr. 22:12 UTC

Peļņas

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026. g. 3. febr. 22:10 UTC

Peļņas

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026. g. 3. febr. 22:10 UTC

Peļņas

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026. g. 3. febr. 22:10 UTC

Tirgus saruna

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026. g. 3. febr. 22:10 UTC

Peļņas

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026. g. 3. febr. 22:09 UTC

Peļņas

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026. g. 3. febr. 22:09 UTC

Peļņas

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Salīdzinājums

Cenas izmaiņa

Denali Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

45.12% augšup

Prognoze 12 mēnešiem

Vidējais 33 USD 45.12%

Augstākais 40 USD

Zemākais 25 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Denali Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Denali Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

13.355 / 16.44Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Noskaņojums

By Acuity

305 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.